TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

• Status: NOT_YET_RECRUITING
• Trial end date: 2032-05-14

Summary

The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

• Phase: PHASE1

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: abiraterone; darolutamide